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Neurological diseases (ND) afflict hundreds of millions of people worldwide and constitute 12% of total deaths of 
the population all around the world. According to a global study conducted by the World Health Organization, 8 
out of 10 disorders in the 3rd highest disability classes are neurologic problems. Commonly they have disabling 
consequences, compromising severely the quality of the life of affected subjects. Often therapeutic strategies are 
limited in efficacy. Limitations lie with the enormous fragility of the so complex structure and functions 
accomplished by the central nervous system, together with the presence of the barrier between the tissue and the 
blood limiting the penetration of drugs. For these reason new strategies to protect the brain are essential. One 
way might be the enhancement of local biomolecular mechanisms (metabolizing enzymes, transporters, etc.). 
However, increasing evidence underline that our knowledge of the brain is still partial, and information cannot 
simply be derived from other well-known organs such as the liver. This is the case for the brain cytochrome P450 
enzymes, showing differential cellular localization, brain regional expression and modulation. 
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Neurological diseases (ND) afflict hundreds of millions of 
people worldwide and constitute 12% of total deaths of the 
population all around the world [1]. 
Cytochrome P450 enzymes (Cyps) are a heme-containing 
superfamily of detoxifying enzymes, responsible also for the 
bio activation of a large spectrum of endogenous molecules 
and xenobiotic such as antibiotics, steroid, fatty acids, 
vitamins, among others [2-4]. Largely present in liver, they are 
erroneously considered expressed low in the CNS (1-5% of 
liver) [5]. Consistent with the enormous heterogeneity of the 
brain (in cell type, distribution, functions, architecture, etc.), 
bCyps levels are cell/region specific [3], and their localized 
expression may reach levels similar or higher than in the 
hepatocytes [6-8]. In addition, it is recognized that different, 
specific Cyps genes are expressed in the neural tissue, and 
that their regulation should differ from the modulation in 
peripheral tissue. For their particular characteristics, brain 
Cyps sustain essential neurotrophic and neuroprotective 
functions, regulate the neurotransmitters level (such as the 
endogenous GABA-A receptor agonists), maintain the 
cholesterol and the cerebral blood flow homeostasis, act on 
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retinoid clearance and control the temperature [9;10]. 
Moreover, they act in drugs or chemicals 
activation/degradation and the development of specific 
neurological diseases (ND) [11] (Table 1).  
For instance, Cyp2D7 that metabolizes codeine to 
morphine, a potent analgesic, is present in brain with an 
alternative splicing not present in liver [12]. Cyp2A3 is 
induced by β-naphthoflavone in liver, but not in astrocytes 
cells [13]. Similarly, smoke induces both brain, but not 
hepatic, CYP2D6 [14] and CYP2B6 [15]. Moreover, brain CYP 
modulation may be strictly region and cell specific, 
influencing, or even causing, pathological consequences. 
This is the case of nicotine and ethanol induction of brain 
CYP2D6 (Fig 1). Nicotine induces the enzyme in the 
substantia nigra, putamen, brainstem, and only in selected 
cells of the cerebellum, frontal cortex and hippocampus [16]. 
This upregulation negatively affects learning and memory by 
one side [17;18] by  the other side, the CYP2D6 induction 
protects against Parkinson’s disease (PD), and extends the 
effect of levodopa, a common drug for treatment in PD [16]. 
On the contrary, the exposure to pesticides together with 
Table 1. brain Cyps's substrates and their association with neurological pathologies 
Numbers indicate the different brain Cyps. TDCC:2,3,7,8-tetraclhorodibenzo-p-diossine; MCA: 
3-methylcholanthrene; ΒNF: beta-Naphtoflavone; DEET = N,N-diethyl-m-toluamide; MPTP = 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; DHEA: Dehydroepiandrosterone; PD: Parkinson’s Disease. 
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reduced CYP2D6 activity increases the recurrence of PD 
[19,20]. Similarly, poor metabolizers (due to CYP2D6 genetic 
variants) suffer for increased anxiety and impulsivity [21;22], 
which could be justified by lower levels of endogenous 
dopamine or 5 –hydroxytriptamine; it has not been purposely 
declared if that could be explained by lower receptor levels, 
justified by genetic predisposition or due to the previously 
stated CYP2D6 variants [9]. Schizophrenic patients if are 
Cyp2D6 poor metabolizers may suffer from lack of efficacy 
when treated with clozapine, aripiprazole, olanzapine and 
thioridazin, all substrates for the enzyme [21,23]. Ethanol 
specifically induces CYB2D6 in CA1-3 pyramidal cells and 
dentate gyrus granular neurons (hippocampus) and Purkinje 
cells (cerebellum). These cells/brain areas are known to be 
damaged by alcohol [24]. Cyp3A4 in hippocampus is induced 
by drugs used for the temporal lobe epilepsy, with possible 
side effects such as mental and reproductive disorders, acting 
on sexual hormone metabolism [25].  
With respect to the above mentioned these underlines 
three essential points. First, the relevance of brain Cyps in 
CNS homeostasis, second their association in the ND and 
third, the potential to use them as therapeutic targets for 
neuroprotection.  
Taking into account these considerations, recently we 
assayed the use specific brain Cyps (Cyp1A1, 1A2, 
2A3=2A6 in human) to confer in situ (CNS) resistance to 
bilirubin, an endogenous potentially neurotoxic molecule 
displaying a strong topography of damage (cerebellum the 
most damaged area) [13]. The Cyp1A and 2A subfamily are 
largely expressed in liver, where they are able to metabolize 
bilirubin when hepatic glucoronidation is deficient, reducing 
blood concentration and consequently decreasing the risk of 
developing neurological consequences [26-29]. The same Cyps 
are also expressed in neurons and glial cells, and most 
important, prone to be modulated in astrocytes [8;30] making 
them a potential therapeutical tool. To upregulate the Cyps 
expression and increase the bilirubin clearance, we used a 
powerful hepatic Cyps inducer (β-naphthoflavone - BNF). 
This approach allowed us to prove the dual role of bilirubin 
as brain Cyps inducer and substrate, and to improve bilirubin 
clearance and increase cell viability [13]. However, the 
behavior (mRNA expression, activity, mechanisms of action) 
of the brain Cyps we analyzed was strongly different among 
different Cyps (Cyp1A1, 1A2 and 2A3) and region specific. 
First, differently from hepatic Cyps, Cyp2A3 was not 
modulated by BNF, and thus barely efficient in the 
metabolite clearance. Cyp1A1, was upregulated in both 
cortex (after 6H from BNF exposure) and cerebellum 
astrocytes (after 24H), and effective in bilirubin oxidation, 
but only after uncoupling by the “pollutants” 3, 4, 
3′,4′-tetrachlorobiphenyl (TCB). As proposed by Schelzinger 
and Zaccaro, the uncoupling of Cyps from the respiratory 
chain increase the reactive oxygen species (ROS) and in turn 
oxidize bilirubin [27,31]. Despite oxidative stress is usually 
Figure 1. brain Cyps expression and specific induction in the CNS. Numbers 
indicate the different brain Cyps. NI: Nicotine Induced; CSNI: Cell Specifically Nicotine 
Induced. CSEtI: Cell Specifically Induced by Ethanol. 
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considered part of the damaging mechanisms, ROS 
production was unexpectedly not only tolerated but even 
beneficial (improving viability) in our model. What is more, 
we identified the Cyp1A2 as the most relevant brain Cyps in 
lowering the bilirubin cell concentration without need of 
uncoupling [4,32]. Unfortunately, an appropriate Cyp1A2 
modulation was reached only in cerebral cortex (24H), 
confirming again that brain Cyps modulation is region, cell 
type and inducer specific.  
What mentioned before outline the need of a better 
understanding of how to achieve a region-specific 
modulation of the target genes to uses it as a possible 
therapy. However, more and more evidence underline that 
our knowledge of the brain is still partial, and information 
cannot simply be derived from peripheral organs (such as 
liver), it needs to be evaluated specifically in the CNS for 
each pathology.  
The difference in timing and extent of bCyp modulation 
between cortex and cerebellum we observed may be 
explained in several ways. First, most of CYPs are regulated 
by nuclear receptors bearing to the AhR (aryl hydrocarbon 
receptor), CAR (constitutive androstane receptor), PXR 
(pregnane X receptor) and RXR (retinoid X receptor) 
families (reviewed in [33]). Due to the complexity of the CNS, 
they should be differentially (region/cell type specifically) 
expressed [34-38], making bCYPs in one region more prone to 
induction than in another area. Second, and more specifically 
for our study, the differential behavior may be due to a 
different maturational stage of the two regions [39,40] which 
again could influence the level of expression (thus the 
activity) of the pathway involved in bCyp modulation [41,42]. 
Third, strictly looking at the therapeutic goal, different 
metabolic kinetics might be explained also by the presence of 
mRNA splicing variant influencing the substrate specificity 
[43,44]. 
The existence of the blood brain barrier may limit the 
availability/efficacy of the inducer(s). To overcome this 
issues, a more detailed knowledge of the signaling pathway 
available (to modulation) in each area of the brain must be 
acquired. Due to their essential role in brain homeostasis, the 
subtle modulation of bCyps activity should be limited in 
time, allowing the reversal of the effect to the physiological 
activity in order to limit the potential side effects [14].  
Overall, our data emphasize the increasing importance of 
knowledge about bCyps modulation in pharmacological and 
toxicological implications for cerebral drug metabolism, in 
order to use them as an important tool to increase brain 
resistance to neurological diseases. 
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